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Abstract
Cyld encodes a 956–amino acid deubiquitinating enzyme (CYLD), which is a negative regulator of nuclear factor κB and
mitogen-activated protein kinase pathways. Mutations that truncate and inactivate the carboxyl-terminal deubiquitinat-
ing domain of CYLD underlie the development of skin appendage tumors in humans, whereas down-regulation of Cyld
expression has been associated with the development of various types of human malignancies including lung cancer.
To establish an animal model of human CYLD inactivation and characterize the biological role of CYLD in vivo, we
generated mice carrying a homozygous deletion of Cyld exon 9 (CyldΔ9/Δ9mice) using a conditional approach. Deletion
of exon 9 would cause a carboxyl-terminal truncation of CYLD and inactivation of its deubiquitinating activity. In accor-
dance with previous studies, fibroblasts from CyldΔ9/Δ9 embryos had hyperactive nuclear factor κB and c-Jun kinase
pathways compared with control fibroblasts. CyldΔ9/Δ9 newborn mice were smaller than wild-type littermates with a
short and kinky tail and nomajor developmental defects. However, CyldΔ9/Δ9mice died shortly after birth from apparent
respiratory dysfunction. Histological examination of E18.5 CyldΔ9/Δ9 lungs demonstrated an immature phenotype char-
acterized by hyperplasic mesenchyme but apparently normal epithelial, smooth muscle. and endothelial structures.
Our study identifies an important role of CYLD in lung maturation, which may underlie the development of many cases
of lung cancer.
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Introduction
Hereditary mutations of the cylindromatosis tumor suppressor gene
(Cyld ) predispose humans to tumors of skin appendages known as
cylindromas and trichoepitheliomas [1]. These tumors show character-
istics of hair follicle differentiation and are usually benign, although rare
cases of metastatic skin appendage tumors have been described [2]. Ad-
ditional studies have associated Cyld down-regulation with the develop-
ment of other types of human cancer including hepatocellular, colon,
lung, and cervical cancers as well as multiple myeloma [3–9]. These
findings highlight a broad tissue homeostatic activity of Cyld.
Abbreviations: JNK, c-Jun kinase; MEF, murine embryonic fibroblast; NF-κB, nuclear
factor κB; NSCLC, non–small cell lung cancer; TNF, tumor necrosis factor; TRAF,
TNF-receptor–associated factor
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Zhong et al. [4] have provided compelling evidence for an important
role of Cyld in lung cancer development. Cyld was shown to be down-
regulated in nine non–small cell lung cancer (NSCLC) cell lines and
in more than 60% of NSCLC cancer specimens tested. Importantly,
exogenous expression of wild type but not catalytically inactive CYLD
in NSCLC cell lines suppressed their growth. These findings identify a
broad growth-suppressive role of CYLD in NSCLC development,
which depends on its deubiquitinating activity.
Cyld codes for a 956–amino acid deubiquitinating enzyme
(CYLD), which can inhibit activation of the transcription factor
nuclear factor κB (NF-κB) by members of the tumor necrosis fac-
tor (TNF) receptor family (reviewed in Massoumi and Paus [10]).
Notably, all the identified mutations of Cyld in human cylindromas
are predicted to cause carboxyl-terminal truncations and inactivate
the deubiquitinating domain of CYLD and its ability to inhibit
NF-κB [1,11,12]. In addition to its effect on NF-κB, CYLD was
shown to inhibit the activation of c-Jun kinase (JNK) and p38 in
response to innate immunity stimuli [13,14]. The effects of CYLD
on the NF-κB and mitogen-activated protein kinase pathways seem
to be mediated at least in part through its ability to interact with
TNF-receptor–associated factors 2 and 6 (TRAF2 and TRAF6),
IκB kinase γ, transforming growth factor β–activated kinase 1, and
Bcl3 (reviewed in Massoumi and Paus [10]).
Three groups reported the initial phenotypic characterization of
mice with targeted inactivation of both Cyld alleles (Cyld−/− mice).
Reiley et al. [15–17] identified a critical role for CYLD in thymocyte
development and Tand B lymphocyte activation. Massoumi et al. [18]
reported an increased susceptibility of Cyld−/− mice to chemically in-
duced skin tumors. This group went on to show that the development
of skin tumors in Cyld−/− mice is associated with elevated cyclin D1
expression in Cyld−/− keratinocytes, which is NF-κB–dependent. Fi-
nally, Zhang et al. [19] reported increased colonic inflammation and
colon cancer incidence in Cyld−/− mice compared with wild-type
mice, after azoxymethane and dextran sulfate sodium administration.
The three aforementioned teams inactivated Cyld by disrupting the
translation-initiation-ATG–containing exon (exon 2). A fourth team
reported recently the disruption of B-cell homeostasis in mice over-
expressing solely an alternatively spliced CYLD product, which is
catalytically active but lacks the TRAF2 and IκB kinase γ–interacting
domains [20]. However, none of the targeting approaches mentioned
mimic the identified mutations of Cyld in human tumors, which dis-
rupt the catalytic domain of CYLD.
The present study used a conditional approach to introduce and
characterize phenotypically a carboxyl-terminal truncating mutation
of Cyld that mimics the characterized oncogenic human mutations.
Our approach revealed a previously unidentified role of Cyld in lung
Figure 1. Generation of CyldΔ9/Δ9 mice. (A) The gene targeting strategy for inactivation of murine Cyld. Schematic representation of the
exon/intron arrangement of the targeted Cyld locus on mouse chromosome 8, the targeting vector, and the conditional Cyldflx9 locus
before and after Cre-mediated recombination. The relative positions of loxP sites (filled circles), exons 7 (E7), 8 (E8), 9 (E9), 10 (E10), 11 (E11),
12 (E12), and 13 (E13), and primers used for RT-PCR (F1, R1) and genomic DNA PCR (F5, F6, R6) are also indicated. The positions of the
neomycin resistance gene (neo) and the thymidine kinase gene (tk) in the targeting vector are shown by black and white rectangles, respec-
tively. (B) RT-PCR of CyldmRNA from fibroblasts isolated from Cyld+/+ and CyldΔ9/Δ9 embryos using primers F1 and R1. GapdhmRNA was
used as a quantitative control. (C) PCR of genomic DNA isolated from tails ofCyld+/+ and CyldΔ9/Δ9mice using the indicated combinations of
primers F5, F6, and R6. (D)Western blot analysis of lysates from fibroblasts isolated from Cyld+/+ and CyldΔ9/Δ9 embryos using an anti-CYLD
polyclonal antiserum. The positions of full-length CYLD (CYLD) and an amino-terminal polypeptide of CYLD (*) are shown.
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maturation and established a valuable mouse model for the delinea-
tion of the tissue-specific role of this tumor suppressor.
Materials and Methods
Targeted Mutation of the Murine Cyld Gene
The Cyld genomic locus was isolated from a 129Ola mouse ge-
nomic library. The targeting vector was designed to flank an exon
9–containing 0.95-kb HgaI-SalI genomic fragment with loxP sites.
The vector also consisted of a 4.95-kb BamHI-HgaI genomic fragment
as the 5′ arm of homology then a loxP-flanked neomycin resistance
gene expression cassette, followed by a second 2.65-kb SalI-ClaI ge-
nomic fragment as the 3′ arm of homology and a thymidine kinase
expression cassette. The neomycin resistance gene was used for the
positive selection of correctly targeted stem cells, and the thymidine
kinase gene was used for the negative selection of incorrectly targeted
embryonic stem cells. After identification by Southern blot (not
shown), correctly targeted embryonic stem cell clones were injected
onto C57/Bl6 blastocysts for chimera production and germ line trans-
mission according to standard procedures [21]. Mice carrying the re-
combined Cyld flx9 locus (Figure 1A) in the germ line were identified
by genomic polymerase chain reaction (PCR) and crossed with cre
transgenic mice expressing the Cre recombinase in the germ line [22].
Mice heterozygous for the deletion of Cyld exon 9 (CyldΔ9/+) were iden-
tified and crossed to generate homozygous mutant mice (CyldΔ9/Δ9).
The following primers were used for reverse transcription–PCR (RT-
PCR) or genomic PCR: F1: 5′-GCAGGCTGTACAGATGGAAC-3′,
R1: 5′-CTCTGCAAATTTCAGGTTGCTGTTG-3′, F5: 5′-
GCAGGCTGTACAGATGGAAC-3′, F6: 5′-CGTGAACAGATGT-
GATGAAGGC-3′, R6: 5′-CTACCATCCCTGCTAACCAC-3′. Ex-
periments on live animals were approved by the Hellenic Ministry
of Rural Development (Directorate of Veterinary Services) and by Bio-
medical Sciences Research Center Al. Fleming’s Animal Research and
Ethics Committee for compliance to FELASA regulations.
Measurement of NF-κB and JNK Activities
The basal and CD40 overexpression–induced activity of NF-κB in
murine embryonic fibroblasts (MEFs) from Cyld+/+ or CyldΔ9/Δ9 em-
bryos was assessed by a luciferase reporter assay or an electrophoretic
mobility shift assay as previously described [12]. The basal and TNF-
induced JNK activity was assessed by the ability of immunopurified
JNK from Cyld+/+ or CyldΔ9/Δ9 MEF to phosphorylate c-Jun in vitro
as previously described [23].
Immunohistochemistry and Immunoblot Analysis
Tissues were fixed in 4% paraformaldehyde in PBS overnight at 4°C
and embedded in paraffin. For immunohistochemistry, tissue sections
were deparaffinized and rehydrated. Endogenous peroxidase activity
was quenched using 0.3% hydrogen peroxide in methanol. Sections
were preincubated with the preimmune serum (rabbit or goat) and
then with the primary antibody overnight at 4°C. The following anti-
bodies were used: anti-human surfactant-associated protein C (SP-C;
C-19; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-Clara
cell 10-kDa protein (CC10; goat, polyclonal anti-rabbit, gift from
Drs Singh and Katyal, University of Pittsburgh), anti-Type 1 cell alpha
Figure 2. CYLD inactivation results in up-regulation of the NF-κB and JNK pathways. Fibroblasts from Cyld+/+ and CyldΔ9/Δ9 embryos were
used to evaluate the activities of NF-κB (A, B) and JNK (C). The basal and CD40 overexpression–induced activity of NF-κB was assessed by a
luciferase reporter assay (A) and an electrophoretic mobility shift assay (EMSA, B). The DNA-binding activity of Oct-1 in the nuclear extracts
used in (B) was used as a quantitative control. The basal and TNF-induced JNK activity was assessed by the ability of immunopurified JNK
from the indicated embryonic fibroblasts (C, lower panel) to phosphorylate c-Jun in vitro (C, upper panel).
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(T1 alpha mAB 8.1.1, Developmental Studies Hybridoma Bank,
University of Iowa), anti-Sox2 (ab15830; Abcam), anti–smooth muscle
actin (Sma; clone 1A4; Abcam, Cambridge, MA), and anti–platelet/
endothelial cell adhesion molecule 1 (PECAM-1) (sc-71871; Santa
Cruz Biotechnology) antibodies. Immunostaining was performed using
the antirabbit and antigoat immunoglobulin G Vectastain and the DAB
staining kits from Vector Laboratories (Burlingame, CA), according to
the manufacturer’s protocol. Sections were counterstained with methyl
green. The expression of CYLD protein was determined by immuno-
blot analysis using a previously described anti-CYLD antiserum [15],
which was a kind gift of Dr. Shao-Cong Sun (M.D. Anderson Cancer
Center, TX).
Microtubule Depolymerization/Regrowth
Murine embryonic fibroblasts were treated with 5 μÌ nocodazole
(Sigma, St. Louis, MO) for 30 minutes to depolymerize microtubules.
Then the drug was washed out, and microtubules were allowed to
regrow for 15 minutes. The cells were subsequently fixed with metha-
nol and processed for immunofluorescence staining using an anti–α-
tubulin antibody (catalog number T5168; Sigma).
In Vitro Wound Healing/Cell Migration Assay
Cell migration was assessed by the ability of the cells to migrate
into a cell-free area. Cells were allowed to form a confluent mono-
layer in a six-well plate. The wound was made by scraping a conven-
tional 20-μl pipette tip across the monolayer. Cell migration was
monitored either after the cells were serum-starved overnight or after
a 30-minute pretreatment of MEF with 5 μÌ nocodazole to induce
microtubule depolymerization. Images of three different segments of
the cell-free area were recorded at 0, 12, and 20 hours, and the dis-
tances traveled by the cells at the front in three different segments of
the wound were measured.
Results
Generation of Mice with Targeted Mutation of Cyld
The purpose of our study was to assess the biological effects of
catalytic inactivation of CYLD in vivo by generating an appropriate
mouse model with mutated Cyld that mimics the identified oncogenic
mutations of Cyld in human patients. Furthermore, a Cre-loxP–based
conditional approach was used for Cyld inactivation to be able to study
the biological role of Cyld in specific tissues. Exon 9 of murine Cyld
was chosen for targeted deletion (Δ9) because it codes for an essential
catalytic motif of the deubiquitination domain of CYLD and its re-
moval places exon 10 and downstream exons out of frame after splicing
Figure 3. Phenotypic characteristics of lungs from wild-type and CyldΔ9/Δ9 mice and embryos. (A) Lateral (upper panels) and ven-
tral (lower panels) views of wild-type and CyldΔ9/Δ9 mice at birth. (B) Buoyancy test of lungs from wild-type and CyldΔ9/Δ9 newborn mice.
(C) Hematoxylin and eosin staining of lung tissue sections from E18.5 wild-type and CyldΔ9/Δ9 embryos.
Table 1. Frequency of Genotypes of Cyld+/+ CyldΔ9/+ and CyldΔ9/Δ9 Embryos and Newborns.
Cyld+/+ Cyld Δ9/+ Cyld Δ9/Δ9
E10.5 (n = 3) 5 (19%) 16 (62%) 5 (19%)
E12.5 (n = 2) 2 (15%) 7 (54%) 4 (31%)
E13.5 (n = 6) 9 (18%) 25 (50%) 16 (32%)
E14.5 (n = 3) 6 (26%) 13 (57%) 4 (17%)
E17.5 (n = 3) 6 (29%) 9 (43%) 6 (29%)
Newborns 9 (18%) 25 (51%) 15 (31%)*
Heterozygous CyldΔ9/+ mice were crossed and the genotype of newborns and embryos of
the indicated embryonic stage were analyzed by genomic PCR. n indicates the number of
litters analyzed.
*All CyldΔ9/Δ9 newborns died shortly after birth.
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to exon 8. Therefore, exon 9 was flanked with loxP sites (floxed) as
shown in Figure 1A, and the mutation was introduced to mouse em-
bryonic stem cells through standard gene targeting procedures. Initially,
we generated heterozygous Cyld+/Δ9 mice by appropriate crosses be-
tween mice that carry two floxed Cyld alleles (Cyld flx9/flx9) with an
X-linked cre transgenic mouse that expresses the Cre recombinase in
the germ line [22]. Cyld flx9/flx9 and Cyld+/Δ9 mice did not have any
macroscopic, histological, or fertility problems. Heterozygous Cyld+/Δ9
were subsequently crossed to generate homozygous CyldΔ9/Δ9. RT-
PCR, genomic PCR, and Western blot analysis confirmed the absence
of exon 9–containing Cyld mRNA and DNA and full-length CYLD
protein in MEF from CyldΔ9/Δ9 embryos (Figure 1, B–D). However,
an approximately 30-kDa polypeptide containing amino-terminal epi-
topes of CYLD was consistently detected in lysates from CyldΔ9/Δ9
MEF but not wild-type MEF lysates (Figure 1D). This finding is con-
sistent with the expression of an amino-terminal fragment of CYLD,
which would lack a functional deubiquitinating domain. To determine
whether CYLD affects the NF-κB and JNK pathways in vivo, MEF from
wild-type and CyldΔ9/Δ9 embryos were used to determine the levels of
NF-κB and JNK activation in response to CD40 activation or TNF, re-
spectively. In accordance with previous studies involving immortalized
cell lines, inactivation of CYLD in ourCyldΔ9/Δ9mice resulted in elevated
NF-κB and JNK activity (Figure 2).
CyldΔ9/Δ9 Mice Die Perinatally from Apparent
Respiratory Dysfunction
CyldΔ9/Δ9 mice were born at normal Mendelian ratios but died
shortly after birth (Table 1). Newborn CyldΔ9/Δ9 mice were smaller
than their wild-type littermates and had short and kinky tails (15 of
15 mice examined), which may underlie a mild skeletal defect
(Figure 3A). These mice did not show any other major external devel-
opmental defects, but their skin color suggested that they rapidly de-
veloped cyanosis. Internal examination revealed that all organs formed.
However, in all newborn CyldΔ9/Δ9 mice examined (8/8), the lungs
failed to float in the buoyancy test in isotonic solution, indicating that
these mice were unable to breathe at birth (Figure 3B). This prompted
Figure 4. Immunohistochemical analysis of developing lungs from wild-type and CyldΔ9/Δ9 embryos. Paraffin sections of lung tissue
from embryos of the indicated stage were immunostained for SP-C (A and B), CC10 (K and L), T1α (E–H), Sox2 (C, D, I, and J), Sma
(M and N), and PECAM-1 (O and P). aw indicates airway; bv, blood vessel.
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us to characterize the phenotypic changes in these lungs and to further
investigate how disruption of CYLD function interfered with lung de-
velopment in CyldΔ9/Δ9 mice.
Abnormal Development of Lungs in CyldΔ9/Δ9 Embryos
Lungs were isolated from CyldΔ9/Δ9 and wild-type embryos at E13.5,
E15.5, and E 18.5, representative of early and late stages of lung develop-
ment, and morphological and marker analyses of these specimens were
performed. Gross morphology and histological analysis (hematoxylin
and eosin staining) of E13.5 and E15.5 lungs showed no abnormalities
in mutants and suggested that the initial stages of lung formation
and branching morphogenesis were apparently unaffected by CYLD
deficiency (data not shown). However, by E18.5, mutant lungs looked
slightly smaller. Hematoxylin and eosin–stained sections showed that
although primitive saccules were present in the distal region of the lung,
these did not seem to be expanded as in wild-type lungs. Moreover, the
interstitial spaces appeared to be thicker and more densely populated
by mesenchymal cells compared with wild-type littermates, suggesting
overall features of lung immaturity (Figure 3C ).
Immunohistochemical analysis showed that at E15.5 lungs from
CyldΔ9/Δ9 and wild-type embryos have a similar pattern of expression
of the distal epithelium marker SP-C and the proximal epithelium
marker HMG transcription factor Sox2 (Figure 4, A–D). At E18.5,
both wild type and mutant lungs have already undergone sacculation.
By this process, distal epithelial tubules evolve into terminal saccules.
This is coincident with flattening of some distal epithelial cells to form
type I alveolar cells resulting in a drastic expansion of air spaces and
thinning of the mesenchyme, as a preparation for birth. T1α labels
type I epithelial cells, which are recognized by their flat morphology
outlining the primitive saccules (reviewed in [24,25]). No difference in
T1α expression was detected between wild type and mutant groups,
suggesting that type I cells could differentiate in the absence of CYLD.
Mutant lungs, however, showed abundant mesenchyme in between
terminal saccules (compare the region depicted by asterisks in Figure 4,
E and G). This is consistent with the apparent inability of these lungs
to perform normal gas exchange subsequently at birth. Our results
strongly suggest that immaturity in CyldΔ9/Δ9 lungs resulted at least
in part from failure to undergo thinning of the mesenchyme. Analysis
of E18.5 lungs did not reveal differences in the pattern or intensity of
staining for SP-C, Sox2, CC10, Sma, or PECAM, suggesting that type
II cells, Clara cells, muscular, and vascular structures were present and
likely normal in CyldΔ9/Δ9 embryos (Figure 4, I–P; data not shown).
Although the defect we described could already explain the lethality of
CyldΔ9/Δ9 mice at birth, we cannot exclude central nervous system or
Figure 5. CYLD inactivation impairs microtubule regrowth after
nocodazole treatment. Microtubules of embryonic fibroblasts from
wild-type or (Cyld+/+) or CyldΔ9/Δ9 embryos were visualized by immu-
nofluorescence before nocodazole treatment (A) or 15 minutes after
nocodazole washout that followed 30 minutes of treatment with
nocodazole (B). A representative experiment of two independent
experiments done in quadruplicates is shown.
Figure 6. Wound-healing assay after nocodazole treatment. Con-
fluent cultures of fibroblasts from wild-type or (Cyld+/+) or CyldΔ9/Δ9
embryos were treated with nocodazole for 30 minutes, and after
nocodazole washout, they were subjected to a standard wound-
healing assay. (A) Phase-contrast images of the wound margins
were acquired 12 and 20 hours after wounding. (B) The distance
that was covered by migrating cells was measured at 12 and
20 hours after wounding and was expressed as percent of the ini-
tial distance that was generated by the wound. The values that are
shown represent means ± SE of average distances traveled by the
cells at four different segments of the wound from four experiments.
Statistical analysis was performed using the Student’s t-test. Statis-
tically significant differences between the values that correspond to
wild-type and CyldΔ9/Δ9 MEF are shown by ** (P value < .01).
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neuromuscular abnormalities as contributing factors. These possibilities
will be investigated in future studies.
CYLD Inactivation Impairs Microtubule Regrowth and
Cell Migration After Nocodazole Treatment
CYLD has been implicated in microtubule dynamics and cell
migration [26]. It is conceivable that the lung maturation defect that
was observed in CyldΔ9/Δ9 embryos is related to the dysregulation of
microtubule reorganization and cell migration associated with cellu-
lar remodeling that takes place during the late stages of embryonic
lung maturation. To investigate this possibility, fibroblasts from
CyldΔ9/Δ9 and wild-type embryos were examined for their ability to
support microtubule regrowth after nocodazole treatment. Micro-
tubule regrowth was clearly delayed in CyldΔ9/Δ9 MEF compared with
their wild-type counterparts (Figure 5). To determine whether the
delay in microtubule regrowth after nocodazole treatment can impair
the migratory ability of CyldΔ9/Δ9 MEF, a wound healing assay was
performed. For this purpose, confluent cultures of wild-type and
CyldΔ9/Δ9 MEF were treated with nocodazole as above and then tested
for their ability to fill a cell-free area that was generated by scraping
the cell monolayer as described in the Materials and methods section.
A significant delay in cell migration of CyldΔ9/Δ9 MEF compared with
wild-type MEF was observed (Figure 6). There was no significant dif-
ference between the migratory ability of CyldΔ9/Δ9 and wild-type MEF
in the absence of nocodazole pretreatment (data not shown). Further-
more, there was no significant difference in the proliferation capacity
of CyldΔ9/Δ9 and wild-type MEF as determined by thymidine incor-
poration (data not shown). Taken together, these results demonstrate
that inactivation of CYLD impairs postdepolymerization microtubule
regrowth and associated cell migration.
Discussion
We have generated a mouse model of CYLD inactivation in all tis-
sues, which revealed a fundamental role of functional CYLD in lung
maturation. Interestingly, the respiratory dysfunction and perinatal
lethality of CyldΔ9/Δ9 mice described in this study was not observed
in other mouse models of Cyld inactivation that have eliminated the
translation-initiation-ATG–containing exon [15,18,19], although one
additional group reported perinatal lethality of mice expressing a
carboxyl-terminally truncated inactive form of CYLD [27]. The reason
for this apparent discrepancy might be the expression and possibly
scaffolding activity of an amino-terminal catalytically inactive CYLD
fragment in our mice, which would be absent from the Cyld−/− mice
generated by Reiley et al., Massoumi et al., and Zhang et al. who tar-
geted exon 2 or exons 2 and 3 for deletion. An alternative possibil-
ity for the difference between our CyldΔ9/Δ9 mice and the Cyld−/−
mice described by Reiley et al., Massoumi et al., and Zhang et al. is
that deletion of exon 2 or exons 2 and 3 allows for expression of an
amino-terminally truncated and catalytically active CYLD polypeptide,
the translation of which is initiated at an in-frame methionine codon
downstream from exon 3.
The principal histological characteristic of lungs from E18.5 Cyld Δ9/Δ9
embryos was an abnormally thick mesenchyme that did not allow
proper formation of the alveolocapillary barrier. The enlarged mesen-
chymal layer of the lung could be due to impaired apoptosis and/or
enhanced proliferation of mesenchymal cells or excessive epithelial to
mesenchymal transition. The increased NF-κB activity that charac-
terizes CYLD loss of function would be consistent with these possibil-
ities [28–30]. In addition, the hyperplastic lungmesenchyme could have
resulted from abnormal microtubule rearrangements and disturbed cell
migration during the late stages of lung development. This possibility is
supported by the role of functional CYLD in microtubule dynamics as
shown by Gao et al. [26] and the present study.
The immature lung phenotype of CyldΔ9/Δ9 mice resembles the
phenotype of mice with parathyroid hormone–related protein de-
ficiency or enzymatic deficiencies that affect the structure of the glyco-
saminoglycan heparan sulfate [31–33]. Additional studies will be
required to define more precisely the mechanism by which CYLD acts
in maturation of the distal lung and whether CYLD exerts its effects
directly in the mesenchyme or through the epithelium.
Down-regulation of CYLD has been associated with the develop-
ment of lung adenocarcinomas [4]. Importantly, both embryonic lung
maturation and the growth suppression of Cyld-deficient lung adenocar-
cinoma cell lines depend on the integrity of the catalytic domain of
CYLD (present study and Zhong et al. [4]). It is conceivable that CYLD
may regulate cellular activities and pathways in different cell layers and
thus influence tumor initiation and/or progression.
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